Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 16Phase 3 14Phase 2/3 3Phase 1/2 2Phase NA 1Phase 4 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 39Pancreatic Neoplasms 27Rectal Neoplasms 21Stomach Neoplasms 20Colonic Neoplasms 16Esophageal Neoplasms 11Neoplasm Metastasis 7Lymphoma, Large B-Cell, Diffuse 7Gastrointestinal Neoplasms 7Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Liver Neoplasms 4Cholangiocarcinoma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Prolymphocytic 2Glioblastoma 2Gastrointestinal Diseases 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Oxaliplatin × Clear all
NCT05919264 2026-05-12

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06385925 2026-04-24

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2 Recruiting
440 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡